Requested funding: $13,935,441

Points for Consideration:

- The project leverages the team and know-how gained in a Disease Team I project
- This project is at the most advanced development stage of the projects in the CIRM portfolio targeting blood diseases
- Sickle cell disease has a high unmet medical need and this approach allows for a chance to detect evidence of biologic activity early in the trial in support of CIRM's strategic goal to demonstrate clinical proof-of-concept

Staff Recommendation: Fund

Application #: DR3 -07078

Type application: Disease Team Award, Early Translation Allowance Pathway (IND-enabling studies and file IND)

Tier, Average Score: Tier 2, 67

Title: Embryonic Stem Cell-Derived Chondroprogenitor Cells to Repair Osteochondral Defects

Disease Target: Osteochondral defects

Approach: Allogeneic hESC-derived chondrocyte progenitors with a biologic scaffold

Requested funding: $13,423,503

Points for Consideration:

- The project leverages the team and know-how gained in a completed Early Translation project
- This project is at the most advanced development stage of Early Translation projects in the CIRM portfolio targeting cartilage disorders and uniquely focuses on a pluripotent-derived progenitor cell
    - An Early Translational Development Candidate Feasibility Award (TR3-05709) to develop an autologous dermis isolated stem cell-derived tissue engineered product for the treatment of focal cartilage defects recently initiated.
    - An Early Translational Award (TR2-01829) is a small molecule to induce chondrocyte differentiation of resident MSCs for the treatment of osteoarthritis.
- There are no funded Disease Team Awards or Strategic Partnership Awards in the CIRM portfolio in cartilage disorders

Staff Recommendation: Fund